{'fraction_non_alphanumeric': 0.01973382285452042, 'fraction_numerical': 0.012391005048187242, 'mean_word_length': 5.374269005847953, 'pattern_counts': {'":': 0, '<': 2, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Effects of Pemetrexed and Docetaxel Combined with Cisplatin in the Treatment of Non-Small Cell Lung Cancer

AbstractPurpose: To compare the clinical effects of pemetrexed and docetaxel combined with cisplatin in the treatment of patients with non-small cell lung cancer.Â Methods: A total of 58 patients with non-small cell lung cancer who were enrolled between January 2017 and January 2018 were enlisted into a randomized digital table. Twenty-nine patients who have received treatment with combined pemetrexed and cisplatin were assigned to the pemetrexed group whereas for the other 29 patients which were treated with docetaxel and cisplatin combined, were assigned to the docetaxel group to verify the calculated clinical treatment efficiency of the patients with non-small cell lung cancer, SVCAM-1 and alCAM-1 concentrations and to evaluate the quality of life scores of the patients after half a year as well as the incidences of adverse reactions following the treatments provided.Â Results: The differences in SVCAM-1 and alCAM-1 concentrations, and incidence of adverse reactions in patients with non-small cell lung cancer in the docetaxel group as compared with patients in the pemetrexed group after the treatments were statistically significant (P<0.05) where the calculations were performed with data sets gathered from and between the two groups. Additionally, SVCAM-1 and alCAM-1 concentrations in patients in both pemetrexed group and docetaxel group demonstrated significant differences in concentrations before and after the treatments were provided, P<0.05. The comparative studies of the effects of the treatments on the quality of life scores and clinical treatment efficiency between the two groups after half a year, P>0.05, demonstrated no analytical significance.Â Conclusion: Both pemetrexed combined with cisplatin and docetaxel in combination with cisplatin as forms of treatments demonstrated significant effects in patients with non-small cell lung cancer. However, based on our study, it was found that the combined treatment involving pemetrexed and cisplatin can further reduce adverse reactions and thus, is worthy of clinical application.Â 